Holen Sie sich die Stockscreener-App
158.44
0.47%
0.74
Handel nachbörslich:
158.85
0.41
+0.26%
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera’s Strong Growth Potential and Market Leadership Justify Buy Rating - TipRanks
Natera Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 EndofMonth & Fast Entry Momentum Trade Alerts - sundaytimes.kr
Non-invasive Prenatal Testing Market Set to Witness Massive - openPR.com
Natera price target raised to $195 from $185 at Morgan Stanley - MSN
5 Revealing Analyst Questions From Natera’s Q2 Earnings Call - TradingView
Natera Q2 Earnings Call Highlights Strong Growth, Raises Revenue Guidance and Announces New Product Launches and Innovations - AInvest
1 ‘Strong Buy’ Stock Analysts Think Will Soar 62% - Yahoo Finance
Natera (NTRA) Is Up 14.1% After Raising Revenue Guidance and Launching New Prenatal Test – Has the Bull Case Changed? - simplywall.st
Natera Insider Sold Shares Worth $958,059, According to a Recent SEC Filing - MarketScreener
Natera director Sheena Jonathan sells $958k in NTRA stock - Investing.com
Natera director Sheena Jonathan sells $958k in NTRA stock By Investing.com - Investing.com Canada
Natera Inc. Reports Strong Growth and Strategic Advances - TipRanks
Natera at Canaccord Conference: Growth and Innovation in Focus - Investing.com
Natera at Canaccord Conference: Growth and Innovation in Focus By Investing.com - Investing.com Australia
New noninvasive prenatal test can screen for CF, other genetic diseases - Cystic Fibrosis News Today
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures - TradingView
Natera Surges 3.35% as Daily Volume Slumps 49.12% to 310M Dollar Ranking 335th in Market Activity - AInvest
Natera Stock Jumps 13.69% In 3 Days As Technicals Signal Bullish Reversal - AInvest
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY) - The Globe and Mail
Natera And 2 Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Mixed Analyst Opinions on Healthcare Stocks Cytek Biosciences, Natera, and Warby Parker - AInvest
Natera introduces prenatal test for detecting inherited conditions - MSN
Natera raises revenue guidance to $2.1B and targets margin expansion through AI-driven efficiencies - MSN
Evercore Gives Natera (NTRA) Outperform Rating - MSN
Natera's Signatera test to be covered under Medicare - MSN
How much upside does Natera Inc. haveAnalyst Upgrade Watch - thegnnews.com
What is the Moat Score of Natera Inc.Free Growth Stock Screener - mustnews.co.kr
Natera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Natera, Inc. (NASDAQ:NTRA) Q2 2025 Earnings Call Transcript - Insider Monkey
What technical models suggest about Natera Inc.’s comebackFree Secure Capital Picks With Upside Potential - Newser
14 Best Aggressive Growth Stocks to Buy According to Analysts - Insider Monkey
Natera shares surge 17% after strong Q2 results and upgraded guidance - Invezz
Natera Stock: Growth or Bubble? - StocksToTrade
Natera Inc. Stocks Soar After Impressive Q2 Results - timothysykes.com
Natera’s Stock Leaps Amid Clinical Trial Success - StocksToTrade
Natera (NTRA) Shares Surge on Q2 Outperformance: Is This a Sustainable Growth Story or a Short-Term Overreaction? - AInvest
Natera price target raised to $200 from $194 at Baird - TipRanks
Why Are Natera (NTRA) Shares Soaring Today - Yahoo Finance
Natera Gets First Nod for $8.25 Million Prenatal Test Settlement - Bloomberg Law News
Natera (NTRA) Is Up 5.6% After Raising Revenue Outlook and Launching New Prenatal Test - simplywall.st
Natera’s Latest Achievements Elevate Prospects Post-World Transplant Congress - timothysykes.com
Natera Stock (NTRA) Soars 14% on Strong Financial Results - TipRanks
Natera’s Strong Growth and Strategic Advancements Justify Buy Rating - TipRanks
Natera 2025 Q2 Earnings Deepened Losses Amid Revenue Surge - AInvest
Natera stock price target raised to $255 from $251 at RBC Capital - Investing.com Canada
Bernstein SocGen raises Natera stock price target to $205 on strong revenue - Investing.com
Natera, Inc. shares rise 15.18% premarket after reporting a 32.2% revenue increase in Q2 and raising 2025 outlook. - AInvest
RBC Raises Price Target on Natera to $255 From $251, Keeps Outperform Rating - MarketScreener
Natera price target raised to $200 from $195 at BTIG - TipRanks
Natera's Q2 2025: Unraveling Contradictions in Signatera Growth, Women's Health Impact, and Japanese ASP Aspirations - AInvest
Natera stock price target raised to $215 from $200 at TD Cowen - Investing.com Canada
Earnings call transcript: Natera Q2 2025 sees revenue beat, stock surges - Investing.com UK
Natera's Genetic Gambit: Pioneering the Future of Prenatal Diagnostics Through Innovation and Market Expansion - AInvest
Natera, Inc. shares rise 13.40% premarket after launching Fetal Focus, a noninvasive prenatal test for inherited conditions. - AInvest
Natera Stock Soars 13.4% on 32.2% Revenue Surge - AInvest
Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6% - Yahoo Finance
Natera Q2 2025 slides: 32% revenue growth drives raised guidance, stock surges - Investing.com Canada
Natera Inc (NTRA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance By GuruFocus - Investing.com Canada
Natera Targets $2Bln Revenue In 2025 - RTTNews
Natera Reports Second Quarter 2025 Financial Results - BioSpace
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):